U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06908434) titled 'A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation' on March 19.
Brief Summary: The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumors Harboring a TP53 Y220C Mutation
Intervention:
DRUG: GenSci128 tablets
GenSci128 tablets have three specifications, including 50mg, 200mg, 500mg, and are taken in combination with the doctor's advice in diffe...